Comparative Pharmacology
Head-to-head clinical analysis: BANZEL versus GABAPENTIN ENACARBIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BANZEL versus GABAPENTIN ENACARBIL.
BANZEL vs GABAPENTIN ENACARBIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Gabapentin enacarbil is a prodrug of gabapentin. It binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulates neuronal excitability and pain transmission.
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
Initial: 600 mg orally once daily; titrate to 600 mg three times daily; max 2400 mg/day divided three times daily.
None Documented
None Documented
Clinical Note
moderateGabapentin enacarbil + Venlafaxine
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Venlafaxine."
Clinical Note
moderateGabapentin enacarbil + Nefazodone
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone."
Clinical Note
moderateGabapentin enacarbil + Stiripentol
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
Terminal half-life of gabapentin: 5–7 hours in patients with normal renal function. Renal impairment prolongs half-life proportionally to creatinine clearance decline.
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
Renal: 100% as unchanged gabapentin (prodrug is rapidly hydrolyzed to gabapentin after absorption). No biliary or fecal elimination of active drug.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
Gabapentin enacarbil + Pomalidomide
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pomalidomide."